Liposomal glutathione in human clinical trials: doses, durations, ingredient forms and outcomes
Formulator’s summary: One published human pilot study of oral liposomal glutathione enrolled 12 healthy adults, compared 500 mg/day and 1,000 mg/day over four weeks, and reported changes in glutathione stores and selected immune-function markers. Its small, open-label, uncontrolled design limits interpretation; it does not establish a general dose recommendation or demonstrate equivalence to any commercial powder.
Review at a glance
- Ingredient studied: oral liposomal glutathione
- Human trial identified: one four-week pilot study in 12 healthy adults
- Dose arms reported: 500 mg/day and 1,000 mg/day
- Study form: liposomal glutathione; the retrieved record does not establish equivalence to Bionutricia’s catalogue material
- Catalogue specification: powder with 40–50% L-glutathione; soluble in water
How the review was assembled
This review focuses on published human research directly addressing oral liposomal glutathione, with the aim of distinguishing findings from non-liposomal glutathione research and from laboratory or animal work. A PubMed search in this run returned no records. A separate ingredient-literature search returned records with incomplete titles and objective-only summaries; those records do not provide adequate evidence to compare additional human trials, doses, durations, or outcomes. The single fully verifiable trial record was checked against its primary PubMed and PubMed Central records.
The literature retrieved here therefore supports a narrow review rather than a comparative clinical catalogue. Non-liposomal glutathione studies and records with unclear human status are not treated as evidence for liposomal glutathione.
What human study details are verifiable?
The directly relevant human record is Sinha et al., “Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function,” European Journal of Clinical Nutrition, 2018; 72(1):105–111. DOI: 10.1038/ejcn.2017.132; PMID: 28853742; full text: PMC6389332. The publisher record describes a one-month pilot clinical study of daily oral liposomal glutathione at two dose levels in 12 healthy adults. The 500 mg/day and 1,000 mg/day arms were assessed over four weeks. The authors reported increases in glutathione stores and changes in selected immune-function markers; they reported no differences between the two dose groups and noted limited statistical power.
This was an open-label pilot without a placebo or untreated control group. It was short and small, so the findings should be read as preliminary biomarker observations in the studied participants, not as proof of a clinical outcome, long-term safety or a dose-response relationship.
Study table: liposomal versus other glutathione forms
| Record | Form and design | Participants and dose | Duration | Reported finding | Match to catalogue material |
|---|---|---|---|---|---|
| Sinha et al., 2018; DOI 10.1038/ejcn.2017.132; PMID 28853742 | Oral liposomal glutathione; open-label pilot clinical study | 12 healthy adults; 500 mg/day or 1,000 mg/day | Four weeks | Reported increases in body glutathione stores and changes in selected immune-function markers; no difference between dose groups was reported | Not established. The publication record does not demonstrate that the trial material matches the catalogue powder’s marker load, composition, dose basis or manufacturing specification |
| Other liposomal human records returned in this run | Incomplete or objective-only records | Not verifiable from returned metadata | Not verifiable | No outcome comparison is included because the returned summaries do not provide a sufficiently complete title and finding | Not established |
| Non-liposomal glutathione studies | Outside the review’s ingredient-form scope | Not tabulated | Not tabulated | Not used to infer outcomes for liposomal glutathione | Not applicable |
What do the findings mean for ingredient comparison?
The verifiable human study tests oral liposomal glutathione, but its findings cannot be transferred to every liposomal glutathione powder. The publication record does not identify the specific composition and assay details needed to establish that the trial material is equivalent to the catalogue material. A buyer assessing the relevance of the study should compare the published intervention description with the supplier’s current specification and lot documentation, rather than treating the word “liposomal” as a complete identity specification.
The dose arms are details of this pilot’s protocol, not a recommended formulation level. The absence of a reported difference between the two groups does not establish that the doses are interchangeable or that a lower dose is sufficient; the authors noted that the sample size limited statistical power.
Evidence limitations for formulators
- The directly verifiable human liposomal study was a pilot with 12 participants.
- It lasted four weeks and was open-label, without a placebo or untreated control group.
- The dose comparison had limited statistical power, as the authors noted.
- The trial’s intervention is not demonstrated to match the catalogue powder’s composition or assay specification.
- Search results for other records did not provide sufficient verified metadata and findings to include them as additional human outcome evidence.
These constraints mean this article can describe the one verifiable study’s design and reported observations, but cannot support claims about clinical efficacy, long-term outcomes, superiority over non-liposomal glutathione or a universal dose.
Implications for formulators
For technical evaluation, keep the clinical record and ingredient specification as separate documents. The published trial reports a liposomal intervention, while the catalogue product page states a powder containing 40–50% L-glutathione, soluble in water, with a certificate of analysis issued per lot. Those details do not by themselves establish that the trial material and catalogue material are identical. Review the current specification and lot certificate alongside the paper before drawing a formulation-level comparison.
The Liposomal Glutathione Powder bulk product page lists the catalogue specification. For general documentation checks, see the COA requirements guide.
Supplying liposomal glutathione and related ingredients in bulk
The catalogue lists Liposomal Glutathione Powder — Bulk Supply, with its product page stating a 40–50% L-glutathione content, a water-soluble powder form and a certificate of analysis per lot. Related catalogue items include Liposomal B Complex powder and Liposomal D3 powder; each product specification should be reviewed independently rather than assumed to share glutathione’s composition. Bulk supply, custom specification, powder forms, lot documentation and export paperwork are described across the published catalogue. Bionutricia’s published quality framework includes FSSC 22000, JAKIM Halal, GMP, HACCP, MeSTI and US FDA facility registration. Buyers should confirm the current specification and documentation appropriate to their own technical review.
Frequently asked questions
What human doses of liposomal glutathione have been reported? The verifiable pilot study tested 500 mg/day and 1,000 mg/day. These are study arms, not general formulation recommendations.
How long did the human liposomal glutathione study last? The pilot study lasted four weeks and included 12 healthy adults. Its open-label design and lack of a placebo or untreated control group limit interpretation.
What outcomes did the study report? The authors reported increases in glutathione stores and changes in selected immune-function markers. The findings are preliminary observations from a small pilot, not evidence of a clinical health outcome.
Does the trial establish that the catalogue powder has the same results? No. The publication record does not establish that the trial intervention matches the catalogue powder’s composition, assay specification or manufacturing details. The study and product specification should be assessed separately.
Does the evidence establish a preferred dose or a dose-response relationship? No. The study reported no differences between its two dose groups and noted limited statistical power. The tested amounts should not be treated as a universal dose recommendation.
Request the specification for liposomal glutathione
Request the specification and certificate of analysis for our Liposomal Glutathione Powder.
